Clinical Trials
3 trialsNCT06959537 2026-05-20
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05491226 2026-04-20
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT06488378 2025-08-22
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Recruiting